Scotiabank Initiates Coverage On Adaptimmune Therapeutics with Sector Outperform Rating, Announces Price Target of $3.15
Portfolio Pulse from Benzinga Newsdesk
Scotiabank has initiated coverage on Adaptimmune Therapeutics (NASDAQ:ADAP) with a Sector Outperform rating and a price target of $3.15.
May 30, 2024 | 2:35 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Scotiabank has initiated coverage on Adaptimmune Therapeutics with a Sector Outperform rating and a price target of $3.15, indicating a positive outlook for the stock.
The initiation of coverage with a positive rating and a specific price target by a reputable financial institution like Scotiabank is likely to boost investor confidence and could lead to a short-term increase in the stock price of Adaptimmune Therapeutics.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100